Interview with Cao Lin, Founder of Nanjing Vazyme Biotech Co., Ltd, Chairman, CEO

Providing high-quality products and solutions

Vazyme will highlight reagents and instruments for Coronavirus testing at Medlab Middle East.

By Deepa Narwani, Senior Editor

Vazyme is a biotechnology company that has made unique contributions to the field of life sciences. Since it was founded in 2012, the technology-oriented enterprise has focused on a customer-first approach.

At Medlab Middle East, the company will be highlighting its products such as reagents and instruments for Coronavirus testing. The reagent products are divided into three categories – nucleic acid detection, antibody detection, and antigen detection. While instruments displayed will include automatic nucleic acid extraction instrument and quantum dot instruments. Vazyme’s IVD products have high sensitivity and safety and provide accurate results that can be customised to meet customer needs.

Cao Lin, Founder of Nanjing Vazyme Biotech Co., Ltd, Chairman, CEO said: “Thanks to the opportunity provided by Medlab Middle East 2021, Vazyme expects to meet more overseas medical and healthcare industry professionals and enterprises. With steady development in the China market, we are actively looking to make inroads into the international market.”

According to Lin, Medlab Middle East 2021 also offers a chance for healthcare and trade professionals to see the potential of an online event platform. “Vazyme is actively engaged in digital marketing and want to promote our mission and bring high-quality products around the world,” he added.

COVID-19 response

Vazyme’s Novel Coronavirus project team made considerable efforts to promote the company's resumption of work and production during the peak of COVID-19, to meet the needs of pandemic prevention and control. The company offered a complete solution of diagnosis and treatment plan to both the domestic and international markets, right from nucleic acid testing raw material (300 million kits), Novel Coronavirus antibody detection kit (30 million kits), antigen detection kits, nucleic acid testing kits to the neutralizing antibodies and vaccines evaluation reagent. The team also volunteered to go overseas to help the global fight against COVID-19.

Furthermore, Vazyme’s team members kept fighting on the front lines of the COVID-19 campaign, and continuously conducted clinical sample testing, to validate and optimise product performance.

Lin said: “Keeping the needs of the customers in mind, we will continue to build the core strength of research and development with high standards by optimising our product performance and operation flow for customer satisfaction 24/7.”

In the new normal, shared Lin, it is important to keep a positive attitude and an open mind to industry changes, but companies shouldn’t forget about their core mission.

“As Vazyme holds the value proposition of “Developing Technology to Improve Human Health,” we focus on providing high-quality and considerate service to our customers whenever and wherever they are,” he added.

When asked about future plans, Lin shared a three-pronged approach:

Product: The company plans to increase investment in R&D and innovation, open up a new track in the field of in-vitro diagnosis, use science and technology to help China and the world's bio-safety construction, and help mankind overcome major infectious diseases, tumours and autoimmune diseases.

Market: In the future, Vazyme will continue to develop business in overseas markets, establish overseas market bases, build a worldwide sales network, and promote good technical services and products to the world that could benefit all humankind.

Partners: The company’s partners include BGI, Peking University, Tsinghua University, China CDC, China Sinopharm, large hospitals etc. It expects to meet and build a reliable and strong connection with more professionals, research institutes and enterprises in the life science and IVD fields in the future.

“We wish everyone attending a very successful Medlab Middle East 2021 and hope to meet you all at Z5.D40,” he concluded.